Publications

2025

Patent: Combination of a Treg Depleting agent and checkpoint inhibitor for use in cancer. United States Patent Application 16/978,949; Ref: P15107-03; US Patent #12,186,376 on 1/7/2025. Parveen S is listed as an

investigator

2024

  • Parveen S* and Bishai WR (2024). Role of Glutamine metabolism in tuberculosis pathogenesis: A mini review. Frontiers in Tuberculosis (In Press) (*co-corresponding author) (Review) 

2023

  • Parveen S, Shen J, Lun S, Zhao L, Koleske B, Leone RD, Rais R, Powell JD, Murphy JR, Slusher BS, and Bishai WR (2023). Glutamine metabolism has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis. Nature Communications. PMID: 37973991  

  • Ordonez AA, Saupe F, Kasper CA, Turner ML, Parveen S, Flavahan K, Shin H, Artemov D, Ittig SJ, and Jain SK (2023). Imaging Tumor-targeting Bacteria using 18F-Fluorodeoxysorbitol Positron Emission Tomography, Journal of Infectious diseases. PMID: 37788499 

2021

  • Parveen S, Lun S, Urbanowski ME, Cardin M, Murphy JR, and Bishai WR (2021). Effective host-directed therapy for tuberculosis by targeted depletion of myeloid-derived suppressor cells and related cells using a diphtheria toxin-based fusion protein. Journal of Infectious Diseases. PMID: 33955457

  • Parveen S, Siddharth S. Chueng LS, Kumar A, Murphy JR, Sharma D, and Bishai WR (2021). IL-4 receptor targeting as an effective immunotherapy against triple-negative breast cancer. Molecular Oncology. PMID: 33682324 

  •  Krug S, Parveen S*, and Bishai WR (2021). Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis. Front Immunol. PMID: 33953722 (*co-first author) (Review)

  •  Parveen S, Murphy JR, and Bishai WR. (2021). Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma. Springer Cham. (Book Chapter)

2019

  •  Parveen S., Bishai WR, and Murphy JR. (2019) Corynebacterium diphtheriae: diphtheria toxin, the tox operon and its regulation by Fe2 + -activation of apo-DtxR. Microbiology Spectrum (ASM Press). PMID: 31267892 (Book Chapter)

  •  Kumar P, Kumar A, Parveen S, Murphy JR, and Bishai WR. (2019). Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy. Immunotherapy. PMID: 31361167 (Review)

  •  Cheung LS, Fu J, Kumar P, Kumar A, Urbanowski ME, Ihms EA, Parveen S, Bullen CK, Patrick GJ, Harrison R, Murphy JR, Pardoll DM, and Bishai WR (2019). Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma. Proceeding of National Academy of Sciences USA. PMID: 30718426

  •  Kumar A, Parveen S*, Sharma I, Pathak H, Deshmukh M, Sharp JA, and Kumar S. (2019) Structural and mechanistic insights into EchAMP: A antimicrobial protein from the Echidna milk. Biochimica et Biophysica Acta-Biomembranes. PMID: 30951703 (*co-first author)

    Patent:

  • Methods of treating or preventing cancer with an agent that depletes Tregs and is a checkpoint inhibitor. PCT Filed: PCT / US2019 / 020959; Pub No.: US 2022/0023395 A1. Parveen S is listed as an investigator.

2017

  •  Parveen S, and Reddy M. (2017) Identification of YfiH (PgeF) as a factor contributing to the maintenance of bacterial peptidoglycan composition. Molecular Microbiology. PMID: 28612943

2015

  •  Singh SK, Parveen S, Saisree L, and Reddy M. (2015) Regulated proteolysis of a cross-link specific peptidoglycan hydrolase contributes to bacterial morphogenesis. Proceeding of National Academy of Sciences USA. PMID: 26283368

Patents

2019:

2025: